Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Dextropropoxyphene measurement |
Has measured component |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Dextropropoxyphene measurement |
Component |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely dextropropoxyphene hydrochloride 65 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing propoxyphene hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Product containing aspirin and caffeine and propoxyphene hydrochloride |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
|
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
Has basis of strength substance (attribute) |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely dextropropoxyphene hydrochloride 65 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely dextropropoxyphene hydrochloride 65 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
Has basis of strength substance (attribute) |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
False |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
Has basis of strength substance (attribute) |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Aspirin 389 mg and caffeine 32.4 mg and dextropropoxyphene hydrochloride 65 mg oral capsule |
Has precise active ingredient |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing precisely aspirin 389 milligram and caffeine 32.4 milligram and dextropropoxyphene hydrochloride 32 milligram/1 each conventional release oral capsule (clinical drug) |
Has precise active ingredient |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
3 |
Product containing precisely dextropropoxyphene hydrochloride 65 milligram/1 each conventional release oral capsule (clinical drug) |
Has precise active ingredient |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
1 |
Product containing precisely dextropropoxyphene hydrochloride 32.5 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
Has basis of strength substance (attribute) |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |
Product containing precisely dextropropoxyphene hydrochloride 32.5 milligram and paracetamol 325 milligram/1 each conventional release oral tablet (clinical drug) |
Has precise active ingredient |
True |
Dextropropoxyphene hydrochloride |
Inferred relationship |
Existential restriction modifier (core metadata concept) |
2 |